Dr Reddys Laboratories has informed about a press release dated March 31, 2016, titled ‘Dr. Reddy’s Laboratories Acquires the Rights to Investigational Anticancer Agent E7777 for U.S, Europe and Certain Emerging Markets from Eisai’.
The above information is a part of company’s filings submitted to BSE.